RDW is reported on every routine CBC and most clinicians look at it last. The longevity literature reads it first. The number is not a diagnosis; it is a coefficient of variation of red cell volume. But that simple statistic captures something the other markers miss, which is why it sits in the Levine PhenoAge model and why it has held up across cohorts.
What is RDW?
RDW is the coefficient of variation of red cell volume distribution, expressed as a percentage. The math: standard deviation of MCV divided by mean MCV, times 100. A reading of 13.0% means individual red cells in your circulation vary by ~13% around their mean size. RDW-CV (the standard reading) is what most labs report; RDW-SD is also available but less commonly used.
A homogeneous red cell population (uniform size) gives a low RDW. A mixed population (some macrocytes plus some microcytes, or recently transfused blood plus native cells, or rapid turnover with reticulocytes plus mature cells) gives a high RDW.
Standard reference range: 11.5-14.5% for adults. The lab range is wide; the longevity-optimal band is narrower, sitting under 13.0%.
What is a normal RDW range?
The mortality gradient within the reference range is the striking feature. Patel et al. 2010 meta-analyzed multiple older-adult cohorts and found each 1 percentage-point rise in RDW associated with roughly a 14% higher all-cause mortality hazard, with the relationship continuous from ~12% upward Patel et al. 2010 . The gradient was independent of hemoglobin, MCV, and traditional cardiovascular risk factors.
Felker et al. 2007 examined RDW in the CHARM heart failure trial population (n=2,679) Felker et al. 2007, n=2679 . RDW was the second-strongest predictor of mortality and HF hospitalization, beaten only by age. The signal was independent of NYHA class, ejection fraction, hemoglobin, and standard risk markers.
Longevity-optimal framing:
- <12.5%: optimal.
- 12.5-13.0%: still good.
- 13.0-14.5%: monitor; investigate if trending upward.
- 14.5-16.0%: soft flag; targeted workup warranted.
- >16.0%: hard flag; clinical evaluation.
How it feeds into PhenoAge
Levine et al. 2018 included RDW as one of the nine PhenoAge inputs Levine et al. 2018 . The coefficient is positive and the slope is steep: small absolute differences (12.5% vs 14.0%) move PhenoAge by 1-3 years assuming the other inputs are held equal. Run the calculator to see your personal contribution.
The steepness is unusual among PhenoAge components. CRP and glucose have sharper slopes at the extremes; RDW has a relatively linear gradient across the entire reference range, which is why it is one of the more sensitive levers in the model.
What does a high RDW mean?
Three frames for thinking about why RDW tracks mortality so reliably:
- It integrates multiple stressors. RDW rises with iron, B12, or folate deficiency, with chronic inflammation, with recent blood loss, with hemolysis, with MDS, with chronic kidney disease, and with rapid turnover from any cause. A single elevated RDW can be any of these; persistent elevation in someone without obvious anemia is the more interesting signal.
- It is a sensitive bellwether for hematopoietic stress. The marrow's response to stress is to release cells faster, including reticulocytes and cells that haven't had full time to remodel their membranes. This shows up as size variability before it shows up as anemia.
- It correlates with oxidative stress and inflammaging. Multiple cohorts show RDW correlating with hs-CRP, IL-6, and other inflammation markers. The relationship is not fully understood mechanistically, but the empirical pattern is consistent.
What drives it
Causes of elevated RDW, ordered by frequency in adult populations:
- Iron deficiency. Often the earliest CBC change; RDW rises before MCV drops or hemoglobin falls. Confirm with ferritin and iron studies.
- B12 or folate deficiency. Macrocytosis with mixed-population kinetics raises RDW.
- Recent blood loss or transfusion. Mixed population of native and donated cells, or new reticulocytes plus mature cells, transiently raises RDW.
- Chronic inflammation. Anemia of chronic disease may show normal MCV but elevated RDW.
- Hemolysis. Reticulocytosis plus damaged cells produces high RDW. Pair with elevated LDH, low haptoglobin, elevated indirect bilirubin.
- Chronic kidney disease. EPO dysregulation produces irregular erythropoiesis.
- Liver disease. Multiple mechanisms including hypersplenism.
- Myelodysplastic syndrome. Should be considered in adults over 65 with persistent unexplained elevation.
- Recent vigorous endurance training. Mild transient rises in RDW are common in distance runners during heavy training blocks.
Modifiable drivers
The actionable interventions are mostly upstream:
- Replete iron deficiency. Oral ferrous sulfate 65 mg elemental every other day; reassess ferritin and CBC at 12 weeks. RDW typically normalizes within 2-3 months of repleted iron stores.
- Replete B12 and folate. B12 1,000 mcg oral daily for 8-12 weeks then weekly maintenance; folate 400-800 mcg daily. Most macrocytic-pattern RDW elevations resolve within 3 months.
- Treat chronic inflammation. This is the lifestyle and clinical workup pathway: body fat, sleep, infection load, autoimmune control. See the CRP article.
- Reduce alcohol. Heavy drinking raises both MCV and RDW; cessation reverses both within 3-6 months.
- Manage CKD or liver disease. RDW is downstream of these conditions; primary management is on the underlying disease.
There is no supplement that reliably lowers RDW in healthy adults without an underlying deficiency. Marketing claims around "anti-inflammatory" supplements lowering RDW typically reflect placebo or undisclosed iron repletion in the cohort.
Cross-marker patterns
RDW reads best alongside MCV and ferritin:
- High RDW + low MCV + low ferritin: iron deficiency, classic.
- High RDW + high MCV: B12 or folate deficiency, alcohol, mixed cause.
- High RDW + normal MCV: anemia of chronic disease, early iron deficiency, hemolysis, or mixed pathology.
- Normal RDW + low MCV: thalassemia trait, typically.
- High RDW + elevated hs-CRP + low albumin + low lymphocyte percentage: inflammaging signature.
How to act on yours
Testing cadence:
- Healthy adult: annual CBC.
- RDW 13.0-14.5%: redraw in 6 months. Add ferritin, B12, folate, TSH if trending upward.
- RDW >14.5%: targeted workup. Iron studies, B12, folate, reticulocyte count, hemolysis labs (LDH, haptoglobin, indirect bilirubin), liver panel, kidney function.
- RDW >16% without obvious cause: clinical workup with consideration of marrow evaluation in older adults.
Most cases of mildly elevated RDW resolve once the underlying iron, B12, or folate deficiency is corrected. The harder cases are persistent elevation in well-nourished, non-anemic adults; in those, the clinical workup looks for occult inflammation, MDS, or hemolysis.
Counter-view
RDW's status as an independent mortality predictor has prompted some longevity-leaning physicians to argue it should be a primary tracking marker. The skeptical position is that RDW is too downstream and non-specific to act on directly: any of a dozen mechanisms can drive it, and "lowering RDW" is not a coherent intervention. The pragmatic middle: treat RDW like CRP. It is a useful early warning, the actionable work is on identifying and addressing the upstream cause, and chasing the number itself without diagnosing the cause is futile. If your RDW is creeping upward and you are not anemic, do the workup; do not buy the supplements.
